Application of lobetyolin in relieving phenylacetyl metabolite imbalance induced by ethanol

Abstract

The invention discloses a novel application of lobetyolin in improving or relieving phenylacetyl metabolite imbalance induced by long-term low-dose ethanol intake, and belongs to the technical field of biological medicines and functional foods. It is found that lobetyolin can effectively reduce the abnormally increased levels of phenylacetyl glutamine and phenylacetyl glycine in intestinal tract and peripheral blood of intestinal flora derived metabolites due to long-term low-dose ethanol intake, so that phenylacetyl metabolite unbalance is corrected; and further mechanism research shows that the regulating effect strictly depends on complete intestinal flora, so that the lobetyolin indirectly regulates and controls a downstream metabolic pathway by regulating the composition or function of intestinal microorganisms. On the basis, the invention provides application of lobetyolin in preparation of medicines, health foods or functional foods for improving or relieving phenylacetyl metabolite imbalance induced by long-term low-dose ethanol intake.

Description

Technical Field

[0001] This invention belongs to the field of biomedicine and functional food technology, specifically relating to a functional product for intestinal microecological repair. More specifically, this invention relates to the application of codonopsis pilosula, an effective component of the natural drug Codonopsis pilosula, in the preparation of a functional product for alleviating or improving the imbalance of gut microbiota metabolites induced by intestinal barrier damage caused by ethanol intake. Background Technology

[0002] Ethanol consumption has become a major public health concern worldwide, and its harmful effects on health have been widely confirmed. Based on the principle of "minimizing health risks," the Chinese Dietary Guidelines (2022) recommends that adults consume no more than 15 grams of alcohol per day, and clearly states that no amount of alcohol intake has any health benefits, and even small amounts can cause harm.

[0003] The gut, as the first-pass organ for ethanol absorption and metabolism, is the initial and key site for ethanol-induced damage to the body. Ethanol-induced gut microbiota imbalance—including dysbiosis of the microbiome and disruption of its metabolic network—is the core pathological starting point for triggering subsequent systemic physiological dysfunctions. Specifically, long-term ethanol intake can lead to gut microbiota reorganization and altered host metabolic pathways, thereby promoting the excessive production of the gut microbial metabolite phenylacetylglutamine (PAGln) and its homologous metabolite phenylacetylglycine (PAGly), resulting in an imbalance of phenylacetyl metabolite homeostasis.

[0004] These excessively produced metabolites can mediate multi-system health damage through transorganizational signaling via the gut-X-axis. For example, PAGln can induce oxidative stress in vascular endothelial cells, directly leading to endothelial dysfunction and cardiopulmonary injury. Simultaneously, PAGln can activate the adrenaline receptor (ADR)-AMPK signaling pathway, promoting phosphorylation of the mitochondrial splitting protein DRP1, triggering mitochondrial fragmentation and dysfunction, ultimately leading to DNA damage and cellular senescence. These mechanisms have been validated in in vitro experiments using human umbilical vein endothelial cells and lung fibroblasts, as well as in in vivo mouse models.

[0005] The production of phenylacetyl metabolites is the result of co-metabolism between the gut microbiota and the host. Its synthesis begins with dietary phenylalanine. Phenylalanine not absorbed by the small intestine enters the colon and is metabolized by the gut microbiota into phenylpyruvic acid, which is then converted into phenylacetic acid (PAA). PAA then binds with glutamine in the liver to form PAGln, or with glycine in rodents to form PAGly. Studies have shown that (Alcohol-induced gut microbial reorganization and associated overproduction of phenylacetylglutamine promotes cardiovascular disease[J]). Nature Communications (2024, 15(1): 10788.), Long-term ethanol intake can lead to an increase in PAA in feces and a significant increase in PAGln / PAGly levels in blood and feces, marking abnormal activation of the phenylacetyl metabolic pathway. Therefore, CN118621040A considers metabolites such as PAGln as key biomarkers reflecting gut microbiota homeostasis and cardiovascular risk for detection.

[0006] Although the health hazards of ethanol are widely acknowledged, existing interventions still have significant limitations. Mainstream technologies largely focus on accelerating ethanol metabolism in the liver, such as by activating key enzymes like alcohol dehydrogenase and aldehyde dehydrogenase to promote ethanol breakdown. However, they fail to address the core underlying pathogenesis of ethanol-induced gut microbiota disruption and metabolite dysbiosis. Therefore, they cannot effectively block the transmission chain of "gut-derived damage." Currently, there is still a lack of synergistic solutions that can simultaneously and specifically target the repair of gut microbiota imbalance and stabilize the homeostasis of key beneficial / harmful metabolites.

[0007] Against this backdrop, developing a functional ingredient that can precisely target the gut microbiota-metabolite regulatory axis and simultaneously repair and alleviate the imbalance of phenylacetyl metabolites caused by ethanol has significant health-promoting value and application prospects for reducing the health damage caused by ethanol.

[0008] Lobetyolin is a compound found in plants of the genus Codonopsis in the family Campanulaceae (such as Codonopsis pilosula). Codonopsis pilosula Codonopsis pilosula Codonopsis pilosulavar.modesta Sichuan Codonopsis Codonopsis tangshenCodonopsis pilosula is one of the main active components in the dried root and belongs to the alkyne glycoside class of compounds. CN 118370761A discloses the application of codonopsis pilosula glycosides in the prevention or treatment of sepsis via intraperitoneal injection, while CN 120754116A reports its pharmacological activities, including protecting against gastric mucosal damage and exerting anti-atherosclerotic effects by upregulating the expression of aortic tight junction protein. However, despite the existing literature reporting multiple pharmacological activities of codonopsis pilosula glycosides, its ability to improve the imbalance of phenylacetyl metabolites induced by long-term low-dose ethanol intake remains unreported. Summary of the Invention

[0009] The purpose of this invention is to provide a new use for codonopsis glycosides, namely, their application in the preparation of functional products for improving or alleviating the imbalance of phenylacetyl metabolites induced by long-term low-dose ethanol intake.

[0010] This invention has found that codonopsis glycosides have application value in alleviating the imbalance of phenylacetyl metabolites (i.e., elevated PAGln / PAGly levels) caused by long-term low-dose ethanol intake. Oral administration of codonopsis glycosides can affect the metabolism of intestinal flora, thereby reducing the levels of phenylacetylglutamine (PAGln) and phenylacetylgly (PAGly) metabolites and regulating the ethanol-induced imbalance of phenylacetyl metabolites.

[0011] Therefore, the present invention first provides the application of codonopsis glycosides in the preparation of functional products for improving or alleviating the imbalance of phenylacetyl metabolites induced by long-term low-dose ethanol intake.

[0012] The term "long-term low-dose ethanol intake" refers to the continuous and regular intake of low doses of ethanol. Specifically, "low-dose" means daily ethanol consumption below the recommended daily intake of no more than 15g of alcohol (ethanol) for adults as suggested in the "Dietary Guidelines for Chinese Residents (2022)" published by the Chinese Nutrition Society; this is equivalent to the ethanol content of 450mL of beer, 150mL of red wine, or 30mL of spirits. "Long-term" refers to continuous intake for 30 days or more.

[0013] The sources of the lobetyolin described in this invention include, but are not limited to, those from the genus Codonopsis (Codonopsis). Codonopsis It is obtained by extraction, separation, and purification from the roots, stems, fruits, or leaves of plants, or by preparation through chemical or biological synthesis methods.

[0014] The molecular formula of the codonopsis glycoside is C 20 H 28 O8, molecular weight 396.43, CAS number 136085-37-5, specific structural formula is shown below:

[0015] The purity of the codonopsis glycoside is ≥90%, preferably ≥95%, and meets the standards for pharmaceutical or food grade.

[0016] Specifically, the imbalance of phenylacetyl metabolites refers to elevated levels of phenylacetylglutamine and / or phenylacetylglycine in the intestines and / or blood.

[0017] Therefore, the present invention also provides the use of codonopsis glycosides in the preparation of functional products for improving or alleviating elevated levels of phenylacetylglutamine and / or phenylacetylglycine in the intestine induced by long-term low-dose ethanol intake.

[0018] Furthermore, the present invention also provides the use of codonopsis glycosides in the preparation of functional products for improving or alleviating elevated levels of phenylacetylglutamine and / or phenylacetylglycine in peripheral blood induced by long-term low-dose ethanol intake.

[0019] More specifically, the effect of the codonopsis glycosides described in this invention in improving or alleviating the imbalance of phenylacetyl metabolites induced by long-term low-dose ethanol intake is gut microbiota-dependent.

[0020] Based on the above-mentioned effects, the present invention also provides a product containing codonopsis glycosides, which is used to improve or alleviate the imbalance of phenylacetyl metabolites induced by long-term low-dose ethanol intake.

[0021] The product may be a pharmaceutical preparation, a health food, or a functional food containing the active ingredient.

[0022] Furthermore, the pharmaceutical preparation is specifically made by adding pharmaceutically acceptable excipients with an effective dose of codonopsis glycoside as the active ingredient.

[0023] Furthermore, the pharmaceutical preparation is preferably an oral preparation, including but not limited to tablets, capsules, granules, powders, oral liquids, or syrups.

[0024] Furthermore, the aforementioned health food or functional food is specifically made with an effective dose of codonopsis glycoside as the active ingredient, and with the addition of food-acceptable excipients.

[0025] Furthermore, the product form of the health food or functional food may include, but is not limited to, functional beverages, solid beverages, alcoholic beverages, dietary supplements, or other common food forms.

[0026] This invention does not limit the pharmaceutically or food-grade acceptable excipients, but may include any excipient well known to those skilled in the art, such as solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, binders, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, flow aids, flavoring agents, preservatives, suspending agents, coating materials, flavorings, anti-adhesion agents, binding agents, penetration enhancers, pH adjusters, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, encapsulating agents, humectants, absorbents, diluents, flocculants, anti-flocculation agents, filter aids, and release inhibitors, etc., any one or more of these.

[0027] This invention constructed a mouse model of gut microbiota metabolite imbalance induced by long-term low-dose ethanol intake. Animal experiments verified the role of codonopsis glycoside in improving or alleviating ethanol-induced phenylacetyl metabolite imbalance. Compared with the model group and the blank group, the levels of phenylacetyl metabolites PAGln and PAGly in feces and peripheral blood of mice in the model group that were simultaneously given codonopsis glycoside for synergistic effect were significantly reduced. Antibiotic intervention experiments demonstrated that it depends on the regulation of gut microbiota.

[0028] This invention confirms that the natural active ingredient codonopsis glycoside can specifically improve or alleviate the imbalance of phenylacetyl metabolites caused by the common lifestyle of long-term low-dose ethanol intake, thus expanding the application field of codonopsis glycoside. Attached Figure Description

[0029] Figure 1 This is a bar chart of the relative abundance of gut microbiota in mice from different experimental groups based on genus-level statistics, used to demonstrate the ameliorative effect of codonopsis glycosides on gut microbiota structure disorder caused by long-term low-dose ethanol intake.

[0030] Figure 2 This is a comparative chart of the statistical results of the relative abundance ratio (F / B ratio) of Firmicutes and Bacteroidetes in the gut microbiota of mice in different experimental groups, used to show the regulatory effect of Codonopsis pilosula on the imbalance of gut microbiota homeostasis caused by long-term low-dose ethanol intake.

[0031] Figure 3 These are the results of detecting the content of phenylacetyl metabolites PAGln and PAGly in the feces of mice in different experimental groups.

[0032] Figure 4 The results show the detection of the levels of phenylacetyl metabolites PAGln and PAGly in the peripheral blood of mice in different experimental groups.

[0033] Figure 5 The results show the detection of the contents of phenylacetyl metabolites PAGln and PAGly in the feces of mice in different experimental groups under antibiotic intervention.

[0034] The data in the figure were analyzed for differences between groups using a t-test. * indicates... p <0.05, ** indicates p <0.01, *** indicates p <0.001, **** indicates p <0.0001. Implementation

[0035] The embodiments of the present invention will now be described in detail with reference to the accompanying drawings and specific examples. It should be noted that the embodiments are merely illustrative and are intended to provide a thorough understanding of the technical solutions of the present invention and to provide guidance for those skilled in the art to implement and apply the present invention. It should be understood that these descriptions do not constitute any limitation on the scope of protection of the present invention.

[0036] Unless otherwise expressly stated, the production processes, experiments, tests or analysis methods involved in the embodiments of the present invention are all considered to be conventional methods known to those skilled in the art, and only need to be implemented in accordance with conventional conditions or relevant product instructions. The steps and names involved are also generally clear and unambiguous in the art.

[0037] The instruments, equipment, raw materials, reagents, or samples used in the embodiments are not subject to any special restrictions on their source. They are all conventional products that can be purchased through regular commercial channels or prepared by known methods, and their source does not have a substantial impact on the implementation results of the present invention.

[0038] Unless otherwise expressly defined, the scientific and technical terms used in this invention have the meanings commonly understood by one of ordinary skill in the art. In case of any conflict, the definitions in this specification shall prevail.

[0039] The terms “comprising,” “including,” “having,” etc., used in this invention should be understood as open-ended, meaning “including but not limited to.” The term “and / or” includes any and all combinations of one or more of the associated listed items. Quantitative terms such as “a,” “one,” etc., do not exclude multiples; “multiple” or “a variety” refers to quantities greater than or equal to two.

[0040] The terms "preferred", "better", and "exemplary" used in this invention are only used to describe specific solutions or effects and are not intended to limit the necessary scope of the solution or the scope of protection.

[0041] This invention relates to the description of numerical parameters (such as quantity, concentration, temperature, time, etc.), and it should be understood that reasonable deviations naturally exist due to measuring instruments, operational errors, statistical fluctuations, etc. The range of such deviations should be within limits acceptable to those skilled in the art based on common sense.

[0042] The specific experimental protocols involved in the following embodiments of the present invention have all been reviewed and approved by the Ethics Committee of Sichuan Normal University, Animal Experiment Ethics Approval No. 2025LS037, and all operations have strictly followed relevant animal ethics and welfare guidelines.

[0043] The experimental animals were 12-week-old male C57BL / 6 mice weighing 22-26g, purchased from Chengdu Dashuo Experimental Animal Co., Ltd., with experimental animal license number SCXK (Sichuan) 2022-0039.

[0044] Housing environment and conditions: The experimental animal room of Sichuan Normal University was maintained at a room temperature of 20–22℃ and a humidity of 40–60%, with alternating light and dark lighting for 12 hours. Mice had free access to water and food. Mice were fed commercial SPF-grade feed and bedding, and the drinking water was sterile. Mice underwent a two-week acclimatization diet in the experimental animal room before the experiment, with a stocking density of 3 mice per cage.

[0045] Codonopsis glycosides were provided by Chengdu Bencao Tianyun Biotechnology Co., Ltd., and their chemical structure was determined by NMR and mass spectrometry, with a purity of >95% as determined by HPLC. Example

[0046] Example 1

[0047] This embodiment aims to clarify the relationship between long-term low-dose ethanol intake and phenylacetyl metabolite imbalance under the premise of intact gut microbiota, and to verify the corrective effect of codonopsis glycoside on this imbalance.

[0048] Healthy male C57BL / 6J mice were randomly divided into three experimental groups: a blank control group (VC), an ethanol model group (Et), and a ginsenoside-treated group (DSQG+Et).

[0049] The ethanol model group and the codonopsis glycoside administration group established an ethanol-induced phenylacetyl metabolite imbalance mouse model through long-term low-dose ethanol intake. The specific dosage was 39 mg / kg per mouse per day (based on the conversion factor of 15 g ethanol per day for a 70 kg human, and the ethanol dosage was adjusted according to the mouse's weight, mouse dose = human dose × 9.1 × (mouse weight / human weight)), dissolved in physiological saline to prepare an ethanol aqueous solution with an ethanol concentration of 80 mg / mL, and administered orally by gavage for 60 consecutive days.

[0050] During the modeling process, the mice in the Codonopsis pilosula group were simultaneously administered Codonopsis pilosula orally via gavage at a dose of 8 mg / kg per mouse per day (using the conversion factor method, with a Codonopsis pilosula concentration of 40 mg / mL, dissolved in physiological saline).

[0051] The blank control group was administered physiological saline as a control.

[0052] The modeling and intervention period for Codonopsis pilosula glycosides was 60 days, and all mice in the experimental groups had normal access to water during the experiment.

[0053] On day 60, feces (intestinal contents) of mice in each group were collected using the anal stimulation defecation method. Feces from each cage were mixed and combined into one sample. Peripheral blood was collected from the eyeballs to collect serum. Samples were immediately stored at -80°C after collection.

[0054] Fecal samples were collected from mice in each experimental group, and total genomic DNA was extracted. Universal primers were used to amplify the V3–V4 region of 16S rRNA via PCR and followed by second-generation high-throughput sequencing. Bioinformatics analyses, including species annotation, diversity analysis, and community composition analysis, were performed on the obtained sequence data. Finally, relative abundance data of species at the genus level and relative abundance data of specific bacterial groups at the phylum level were obtained. Based on these, the Firmicutes / Bacteroidetes ratio was calculated to assess bacterial community structure and homeostasis.

[0055] from Figure 1 Analysis of the mouse gut microbiota composition at the genus level showed that the gut microbiota of the Et group mice underwent significant remodeling at the genus level, exhibiting a predominance of beneficial bacteria (such as...). Lactobacillus The abundance of bacteria decreases, and potentially harmful bacteria (such as...) Klebsiella pneumoniae The abundance of bacteria increased. After intervention with codonopsis glycosides, the DS+Et group was able to significantly reverse these abnormal changes in bacterial abundance, restoring the bacterial community structure to that of the VC group. This demonstrates that codonopsis glycosides repaired the loss of gut microbiota diversity induced by long-term low-dose ethanol intake.

[0056] Figure 2 Further statistics were compiled. Figure 1 Firmicutes (a key indicator of gut microbiota stability in mice from different experimental groups) Firmicutes ) and Bacteroidetes ( Bacteroidetes The relative abundance ratios (F / B ratios) of the Et group were shown in the figure. The F / B ratio of the Et group was significantly lower than that of the VC group (i.e., the relative abundance of Bacteroidetes increased, or the relative abundance of Firmicutes decreased). However, the intervention of Codonopsis pilosula in the DS+Et group significantly reversed this trend, indicating that Codonopsis pilosula effectively repaired the imbalance of the core homeostasis of the gut microbiota induced by long-term low-dose ethanol intake.

[0057] Fecal and serum samples from homogenized mice in each group were extracted by vortexing with 70% methanol / water solution. The supernatant was collected, deproteinized, and derivatized with 3-NPH / EDC reagent. Quantitative analysis was performed by liquid chromatography-mass spectrometry (LC-MS), and the contents of PAGln and PAGly were determined by external standard method.

[0058] Figure 3The results showed that, compared with the VC group, the Et group had significantly increased levels of PAGln and PAGly in the feces of mice due to the imbalance of phenylacetyl metabolites caused by long-term low-dose ethanol intake. In contrast, the DS+Et group was able to significantly alleviate the increase of PAGln and PAGly levels in the intestine through the intervention of codonopsis glycosides, and significantly corrected the imbalance of phenylacetyl metabolites in the intestine induced by long-term low-dose ethanol intake.

[0059] and then, Figure 4 Serum analysis further revealed the systemic effects of metabolic disorders. The levels of PAGln and PAGly in the serum of mice in the Et group were significantly elevated, indicating that intestinal-derived phenylacetyl metabolites had translocated into the bloodstream. However, intervention with codonopsis glycosides effectively inhibited the increase of these metabolites in the circulatory system, restoring their concentrations to near the normal levels of the VC group. This demonstrates that codonopsis glycosides can significantly inhibit the increase in PAGln and PAGly levels entering the bloodstream, significantly correcting the phenylacetyl imbalance induced by long-term low-dose ethanol intake.

[0060] Example 2

[0061] This embodiment aims to construct a relatively sterile pseudo-sterile model by depleting the intestinal flora of mice using an antibiotic cocktail method, in order to reversely verify the intestinal flora dependence of the balance regulation effect of Codonopsis pilosula glycoside phenylacetyl metabolite.

[0062] Prepare an antibiotic mixed solution using sterile water with vancomycin 0.5 g / L, ampicillin 1 g / L, neomycin 1 g / L, and metronidazole 1 g / L.

[0063] The methods for grouping mice, establishing ethanol modeling, and administering codonopsis glycosides were the same as in Example 1. In addition, all experimental groups of mice were given a mixed antibiotic solution as drinking water to continuously deplete the intestinal flora.

[0064] On day 60, fecal samples were collected from mice in each experimental group to determine the contents of PAGln and PAGly.

[0065] from Figure 5 The results showed that after inducing gut microbiota deficiency with antibiotics, the levels of PAGln and PAGly in the feces of the VC group, Et group and DSQG+Et group were significantly maintained at a low concentration steady state, and their content was much lower than that in the presence of gut microbiota.

[0066] The above results demonstrate that the regulatory effect of codonopsis glycoside on the imbalance of phenylacetyl metabolites induced by long-term low-dose ethanol intake is mediated by intestinal microorganisms and is strictly dependent on the intact intestinal flora. Its efficacy completely disappears under the condition of flora depletion, which excludes the direct effect of this component on the host's phenylacetyl metabolic pathway. This reveals that its core mechanism lies in regulating the composition or function of the intestinal flora, thereby indirectly correcting the imbalance of downstream metabolites.

[0067] Application Example 1

[0068] Weigh 1 kg of codonopsis glycosides, dissolve them in an appropriate amount of sterile water, then add 10 g of ascorbic acid, 10 g of citric acid, 200 g of sucralose and an appropriate amount of edible flavoring in sequence. Dissolve evenly, then continue to add sterile water to 100 L. After sterilization, dispense into containers to prepare the codonopsis glycosides oral liquid drug preparation.

[0069] Application Example 2

[0070] Weigh 1 kg of Codonopsis pilosula extract containing approximately 5 wt% codonopsis pilosula extract, dissolve it in an appropriate amount of sterile water, then add 10 g ascorbic acid, 10 g citric acid, 500 g erythritol, 200 L apple juice and an appropriate amount of edible flavoring in sequence. After dissolving evenly, add sterile water to a volume of 1000 L, sterilize, and fill to obtain the Codonopsis pilosula extract functional beverage.

[0071] Application Example 3

[0072] Weigh 1 kg of Codonopsis pilosula extract containing approximately 5 wt% codonopsis pilosula extract, 10 g of ascorbic acid, 100 g of rock sugar, 200 L of peach juice, and an appropriate amount of edible flavoring. Add 1000 L of liqueur, dissolve evenly, and pour into the container to prepare codonopsis pilosula liqueur.

[0073] The present invention provides, through preferred embodiments, the application of codonopsis glycosides in improving or alleviating intestinal barrier damage and microbial metabolite imbalance caused by long-term low-dose ethanol intake. It should be noted that the above embodiments do not exhaustively describe all details, nor do they limit the present invention to the above-described embodiments. Those skilled in the art can make appropriate improvements based on the above content. All similar substitutions and modifications are obvious to those skilled in the art. Modifications or appropriate changes and combinations made to the methods and applications of the present invention without departing from the content, spirit, and scope of the present invention should be included within the protection scope of the present invention.

Claims

1. Application of Codonopsis pilosula glycosides in the preparation of functional products for improving or alleviating phenylacetyl metabolite imbalance induced by long-term low-dose ethanol intake.

2. The application according to claim 1, wherein the phenylacetyl metabolite imbalance includes elevated levels of phenylacetylglutamine and / or phenylacetylglycine in the intestine and / or blood.

3. Application of Codonopsis pilosula glycosides in the preparation of functional products for improving or alleviating elevated levels of phenylacetylglutamine and / or phenylacetylglycine in the intestine induced by long-term low-dose ethanol intake.

4. Application of Codonopsis pilosula glycosides in the preparation of functional products for improving or alleviating elevated levels of phenylacetylglutamine and / or phenylacetylglycine in peripheral blood induced by long-term low-dose ethanol intake.

5. The application according to claim 1, 3 or 4, characterized in that: Codonopsis pilosula glycosides improve or alleviate ethanol-induced phenylacetyl metabolite imbalance in a gut microbiota-dependent manner.

6. A product containing codonopsis glycosides for improving or alleviating phenylacetyl metabolite imbalance induced by long-term low-dose ethanol intake.

7. The product according to claim 6 is a pharmaceutical preparation made with an effective dose of codonopsis glycoside as the active ingredient and pharmaceutically acceptable excipients.

8. The product according to claim 7, characterized in that: The pharmaceutical preparation is an oral preparation, and the dosage form is selected from tablets, capsules, granules, powders, oral liquids or syrups.

9. The product according to claim 6 is a health food or functional food made with an effective dose of codonopsis glycoside as the active ingredient and food-acceptable excipients.

10. The product according to claim 9, characterized in that: The product form of the health food or functional food is selected from functional beverages, solid beverages, alcoholic beverages, or dietary supplements.

Images